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Hepatocellular carcinoma (HCC) is currently a major challenge
in medicine for its poor prognosis and lack of effective therapeutic
options. The AAA+ ATPase RuvBL1 associates with Hsp90 in sev-
eral multiprotein complexes regulating key cellular pathways such
as cell proliferation, gene expression, chromatin remodeling and
telomere maintenance. In several human cancer, including HCC,
RuvBL1 overexpression correlates with a poor prognosis. Despite
the several functions potentially regulated by RuvBL1, its role in the
onset and progression of HCC is still unknown. We had previously
generated a RuvBL1 hepatocyte-specific knock-out mouse model
and observed by TEM major structural alterations in mitochon-
dria of hepatocytes. Moreover, by a 2D-proteomic screening, we
found that several key mitochondrial proteins and Hsp90 were
significantly reduced in RuvBL1-silenced hepatoma cells in vitro.
Therefore, we aimed to dissect the role of RuvBL1 as a potential
regulator of mitochondria functionality in HCC cells.
First, we found that RuvBL1 targeting by RNAi significantly
impairs mitochondrial respiration (OXPHOS) in normal hepa-
tocytes (AML-12) and hepatoma cell lines (Hepa1-6, HepG2,
Huh7, Hep3B). Live-cell imaging experiments showed a signifi-
cant increase of mitochondrial ROS production and mitochondrial
depolarization in RuvBL1-silenced cells. We next explored the
RuvBL1-Hsp90 axis in mitochondrial functionality. We found that
RuvBL1 is a positive regulator of HSP90AB1 promoter and mRNA
levels, both in hepatoma and normal hepatocyte cell lines. Interest-
ingly, Hsp90 inhibitors (17-AAG, VER-50589) effectively reduced
mitochondrial OXPHOS paralleling RuvBL1 silencing. Analyzing the
LIHC-TCGA database, we found a significant correlation between
RUVBL1 and HSP90AB1 expression in HCC patients, consistently
with our in vitro data. Finally, Gene Ontology analysis performed
on genes differentially expressed in high- vs low-RUVBL1 HCC sam-
ples in the TGCA database, highlighted a significant enrichment of
mitochondria-related terms.
In conclusion, our data uncover a novel role of RuvBL1, possibly
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Introduction: Hepatocellular carcinoma (HCC) is one of the
most common cancers worldwide with more than 800,000 newly
diagnosed cases every year. The late diagnosis, that limits the treat-
ments options, makes this tumor the fifth cause of cancer-related
death. The existing diagnostic procedures are expensive and lack
of adequate sensitivity and the specificity. The growing interest
in the use of circulating miRNAs as reliable biomarkers for cancer
diagnosis opens new perspectives in clinical oncology.
Aim: The main objective of the SERMI4Cancer project is to
develop a portable, user friendly, and cost-effective Point Of Care
(POC) system integrated with the innovative Surface Enhanced
Raman Spectroscopy (SERS) technology for circulating miRNA
detection in HCC patients.
Materials andmethods results: The system allows a label-free
direct detection of the analyte making this technology suitable
for a POC system for multiple applications. The SERMI4Cancer
project includes the development of three components: The miRNA
separation and binding support (polyfunctional matrix); the detec-
tion system consisting of a Portable Raman Spectrometer and
nanostructured SERS Sensor; the data integration system. Molec-
ular beacons targeting miRNAs are immobilized onto silver coated
silicon nanopillars spotted on a nitrocellulose membrane and
incubated with patients’ plasma. Quantifications are performed
with the Raman Renishaw spectrometer, a simple, rapid and
powerful tool yielding a unique “chemical fingerprint” of the
chemical composition of the sample. SERS technology allow a
cost-effective detection of very low concentrations of miRNAs
(attomolar) increasing the accuracy of the diagnostic biomarker
candidate at early stages of the disease.
Conclusion: These results will open new perspectives on HCC
diagnosis that could be useful for the development of a point of care
system with the innovative SERS technology for miRNAs detection
blood samples.
Funding: Supported by the project surface-enhanced Raman
microRNA for cancer(SERMI4CANCER) PORFESR 2014-2020 FVG,
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https://doi.org/10.1016/j.dld.2018.11.110
